Thermo Fisher reports strong 3rd-quarter results
Thermo Fisher Scientific reported strong Q3 2026 results, with revenue up 9%, adjusted EPS up 15%, and adjusted operating margin expanding to 24.5%. The company raised its 2026 outlook, targeting $47.7B-$48.2B in revenue and adjusted EPS of $25.13-$25.43. CEO Marc Casper cited improved end-market conditions and customer activity in pharma, biotech, and industrial markets. The stock price rose over 1% at market opening.
How this was made
The 30-second read
Why it matters
The guidance lift is likely to attract buying interest, especially from investors focused on life‑science equipment and services.
Market read
The earnings beat and guidance raise provide fresh, material information for traders, creating a short‑term upside catalyst.
What to watch
Potential headwinds from supply chain constraints or regulatory changes could temper upside.
Background
Thermo Fisher Scientific (NYSE:TMO) disclosed its Q3 2026 financial results and raised its full‑year outlook, highlighting growth in pharma, biotech, and industrial markets.
Ticker impact
Thermo Fisher reported Q3 results and raised its 2026 revenue and EPS outlook, providing new guidance numbers.
upward pressure as investors price in the higher revenue and EPS outlook
The company lifted its 2026 revenue target to $47.7‑$48.2B and EPS to $25.13‑$25.43, a material upgrade for a large‑cap biotech supplier.
Market effects
Strengthens outlook for life‑science and industrial supply chains, may boost peers in biotech equipment.
Positive for US biotech and industrial sectors, limited global effect.
Modest, primarily US market focus.
Counterpoint
If the guidance is already priced in, the modest 1% price move may be a sell‑off on profit‑taking.
Key entities
- CompanyThermo Fisher Scientific
Global provider of scientific instruments and services.
